eligibility_summary
Adults (≥18) with r/r CD7+ ALL or AML, ECOG ≤2, survival >12 wks, Ph− or Ph+ TKI‑intolerant/failed, adequate organs (O2 sat >92%, AST/ALT ≤2.5×ULN, bili ≤1.5×ULN, CrCl ≥30 mL/min, lipase/amylase ≤2×ULN). Exclude CNS disease/seizures, pregnancy/breastfeeding, active infection, prolonged QT/serious heart disease, chemo ≤2 wks, other malignancy ≤5 y, autoimmune organ damage/immunosuppression, bleeding/coag disorders/thromboembolism, ASCT ≤8 wks, recent trials, or investigator concern.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: 1) CD7 CAR-T cell therapy—gene-modified autologous chimeric antigen receptor T cells targeting CD7, 2) Allogeneic hematopoietic stem cell transplantation (allo-HSCT) used after CAR-T as consolidation (CAR-T bridging to allo-HSCT). Mechanisms: CD7 CAR-T cells bind the CD7 surface antigen on malignant hematologic cells (e.g., T-ALL and CD7+ AML), activating CAR signaling (CD3ζ with co-stimulation) to drive T-cell cytotoxicity and elimination of CD7+ blasts, on-target T-cell aplasia may occur. Allo-HSCT reconstitutes hematopoiesis and provides a graft-versus-leukemia immune effect to sustain remission. Cells/pathways targeted: CD7-expressing leukemic cells, engineered T-cell effector pathways, donor alloimmune anti-leukemia responses.